Beyond JEE, IITs are opening doors with online and executive courses in high-demand fields like AI, robotics, biotechnology, and programming. These programmes include Engineering Mathematics, Genetic ...
It is nearly eight years since healthcare and biotech investor Sam Isaly abruptly stepped down from OrbiMed, the managers of the Worldwide Healthcare Trust (LSE: WWH). In the 22 years in which he was ...
For years, public debate around U.S. dependence on China has focused on semiconductors, consumer electronics, rare earth minerals and industrial manufacturing. Far less attention has been paid to a ...
Biotech valuations are lower relative to other sectors after a decade of stagnation. Denali Therapeutics fell 75% over five years despite its patented blood-brain barrier transport platform. Xenon ...
Arthur Herman’s op-ed, “America Is the Sole Superpower Again,” (Jan. 15) asserts that China is “sliding into a distant second place” in the battle for economic, military and technological supremacy.
SANA’s thesis rests on hypoimmune islet replacement for T1D. UP421 gives it early human validation, and SC451 is the main scalable follow-on asset. SC451’s planned 2026 IND is the primary catalyst ...
As a veteran who was wounded during a mortar attack in Iraq, I’m all too familiar with the fact that our enemies can hit us with little warning. I’ve seen firsthand what happens when we underestimate ...
Why personalized gene editing, genetic resurrections and embryo scoring made our list. Earlier this week, MIT Technology Review published its annual list of Ten Breakthrough Technologies. As always, ...
2025 proved a turning point year for the biotech industry, albeit one wrought with contradiction. The post-COVID slump experienced by the industry seemed due to continue, with the sweeping cuts to the ...
Biotech IPOs hit lowest level in over a decade in 2025 Investors focus on biotechs with mature pipelines and positive trial data Lower interest rates and capital inflows expected to boost sector Jan ...
After five years, Nido Biosciences has reached the end of the road, closing its doors after its lead neurological disease candidate disappointed in a midstage study. Founded by 5AM Ventures’ 4:59 ...
The performance metrics speak volumes. The iShares Biotechnology ETF (NASDAQ: IBB) has climbed 29.51% year to date through December 29, while the State Street SPDR S&P Biotech ETF (NASDAQ: XBI) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results